Scholarlink

Background <p>Systemic inflammation plays an important role in ovarian cancer progression and has been associated with adverse outcomes. Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and systemic immune-inflammatory index (SII) are markers that assess systemic inflammation.</p> Aim <p>To evaluate the association between preoperative systemic inflammatory markers and the selection of neoadjuvant chemotherapy (NACT), and to assess their prognostic impact on overall survival (OS) and progression-free survival (PFS) in patients with advanced-stage serous epithelial ovarian cancer.</p> Methods <p>This retrospective cohort study included patients with FIGO stage III–IV high-grade serous epithelial ovarian cancer. Patients underwent either primary debulking surgery (PDS) followed by platinum-based chemotherapy or NACT followed by interval debulking surgery. Preoperative inflammatory markers (NLR, PLR, and SII) were calculated and dichotomized using median cut-off values (NLR ≥ 4.30, PLR ≥ 222, SII ≥ 1350).</p> Results <p>A total of 239 patients were included; 108 (45.1%) underwent PDS and 131 (54.9%) received NACT. Patients selected for NACT had significantly higher preoperative NLR, PLR, and SII values. In multivariable analyses, high NLR (OR 3.31) and high SII (OR 1.84) were independently associated with increased likelihood of NACT selection, whereas PLR was not. In multivariable analysis, none of the elevated inflammatory markers remained independently associated with prognosis. NACT was associated with inferior OS and PFS after multivariable adjustment. Kaplan–Meier analyses showed that inflammatory markers stratified survival in the PDS group but not in the NACT group.</p> Conclusion <p>Preoperative systemic inflammatory markers, particularly NLR and SII, are strongly associated with the selection of neoadjuvant chemotherapy in advanced-stage serous epithelial ovarian cancer but do not independently predict survival outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Systemic inflammatory markers are associated with neoadjuvant chemotherapy selection but not survival in advanced serous epithelial ovarian cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月20日

查看全文
  • Yakup Yalcin,
  • Kemal Ozerkan

摘要

Background

Systemic inflammation plays an important role in ovarian cancer progression and has been associated with adverse outcomes. Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and systemic immune-inflammatory index (SII) are markers that assess systemic inflammation.

Aim

To evaluate the association between preoperative systemic inflammatory markers and the selection of neoadjuvant chemotherapy (NACT), and to assess their prognostic impact on overall survival (OS) and progression-free survival (PFS) in patients with advanced-stage serous epithelial ovarian cancer.

Methods

This retrospective cohort study included patients with FIGO stage III–IV high-grade serous epithelial ovarian cancer. Patients underwent either primary debulking surgery (PDS) followed by platinum-based chemotherapy or NACT followed by interval debulking surgery. Preoperative inflammatory markers (NLR, PLR, and SII) were calculated and dichotomized using median cut-off values (NLR ≥ 4.30, PLR ≥ 222, SII ≥ 1350).

Results

A total of 239 patients were included; 108 (45.1%) underwent PDS and 131 (54.9%) received NACT. Patients selected for NACT had significantly higher preoperative NLR, PLR, and SII values. In multivariable analyses, high NLR (OR 3.31) and high SII (OR 1.84) were independently associated with increased likelihood of NACT selection, whereas PLR was not. In multivariable analysis, none of the elevated inflammatory markers remained independently associated with prognosis. NACT was associated with inferior OS and PFS after multivariable adjustment. Kaplan–Meier analyses showed that inflammatory markers stratified survival in the PDS group but not in the NACT group.

Conclusion

Preoperative systemic inflammatory markers, particularly NLR and SII, are strongly associated with the selection of neoadjuvant chemotherapy in advanced-stage serous epithelial ovarian cancer but do not independently predict survival outcomes.